TuHURA Biosciences, Inc./NV
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
HURA$1.66+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $995,977 | $3,619,949 |
| Stock subscription receivable | - | 500,000 |
| Other current assets | 659,889 | 501,187 |
| Total Current Assets | 1,655,866 | 4,621,136 |
| Property and equipment, net | 434,887 | 300,639 |
| Operating right-of-use assets | 310,781 | 384,530 |
| Other noncurrent assets | 33,754 | 33,769 |
| Goodwill | 10,738,082 | 10,738,082 |
| In-process research and development | 11,275,000 | 11,275,000 |
| Revolving credit facility debt issuance costs, net | 7,297,883 | - |
| Total Assets | $31,746,253 | $27,353,156 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities: | ||
| Accounts payable and accrued expenses | $3,868,507 | $5,720,241 |
| Revolving credit facility - interest and annual fee | 172,344 | - |
| Revolving credit facility - commitment fee to be settled in shares | 5,000,000 | - |
| Lease liabilities, current | 214,175 | 199,041 |
| Total Current Liabilities | 9,255,026 | 5,919,282 |
| Long-term Liabilities: | ||
| Revolving credit facility borrowings, related party | 3,600,000 | - |
| Lease liability, long term | 192,848 | 303,627 |
| Deferred tax liability | 197,919 | 197,919 |
| Total Liabilities | 13,245,793 | 6,420,828 |
| Stockholders’ Equity: | ||
| Preferred Stock Series A (assumed in Kintara merger); $1.00 par value, 278,530 shares outstanding as of June 30, 2026 and December 31, 2025 | 278,530 | 278,530 |
| Common stock, $0.001 par value, 200,000,000 shares authorized; 63,682,528 and 59,336,104 shares issued and outstanding as of June 30, 2026 and December 31, 2025. | 63,682 | 59,336 |
| Additional paid in capital | 176,107,224 | 161,779,364 |
| Accumulated deficit | (157,948,976) | (141,184,902) |
| Total Stockholders’ Equity | 18,500,460 | 20,932,328 |
| Total Liabilities and Stockholders’ Equity | $31,746,253 | $27,353,156 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.